[
    {
        "file_name": "dovapharmaceuticalsinc_20181108_10-q_ex-10.2_11414857_ex-10.2_promotion agreement.pdf",
        "perturbation": [
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "4.1 Valeant Activities.\n4.1.1 General. Valeant shall conduct the Valeant Activities for the Product in the Specialty in the Field in the Territory in accordance with this Agreement.\n4.1.2 Number of Sales Representatives. Without limiting the generality of the foregoing, [***]) and continuing throughout the remainder of the Term, Valeant shall maintain at least one hundred (100) Sales Representatives with responsibility to Detail the Product in the Specialty in the Territory. Notwithstanding the above, the sole remedy of Dova for breach of this Section 4.1.2 shall be (i) the adjustment to the promotion fee as set forth in Section 6.1.2 and (ii) the termination right set out in Section 12.2.2.",
                "changed_text": "4.1 Valeant Activities.\n4.1.1 General. Valeant shall conduct the Valeant Activities for the Product in the Specialty in the Field in the Territory in accordance with this Agreement.\n4.1.2 Number of Sales Personnel. Without limiting the generality of the foregoing, [***]) and continuing throughout the remainder of the Term, Valeant should endeavor to engage at least one hundred (100) Sales Personnel with responsibility to Detail the Product in the Specialty in the Territory. Notwithstanding the above, the sole remedy of Dova for breach of this Section 4.1.2 shall be (i) the adjustment to the promotion fee as set forth in Section 6.1.2 and (ii) the termination right set out in Section 12.2.2.",
                "explanation": "The original text requires maintaining 'Sales Representatives,' creating a firm obligation. The changed text uses 'Sales Personnel' instead of 'Sales Representatives' making them seemingly interchangeable and softens the obligation to merely an endeavor.",
                "location": "Section 4.1.2"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "5.1 Dova Responsibility. As between the Parties, except as expressly set out herein, all regulatory matters regarding the Product shall be the responsibility of Dova, including responsibility for all communications with Governmental Authorities, including but not limited to FDA, related to the Product, and Dova shall have sole responsibility to seek and/or obtain any necessary approvals of any Product Labeling and the Promotional Materials used in connection with the Product, and for determining whether the same requires approval.",
                "changed_text": "5.1 Dova Responsibility. As between the Parties, except as expressly set out herein, all regulatory matters regarding the Product shall be the responsibility of Dova, including responsibility for all communications with Governmental Authorities, including but not limited to FDA, related to the Product, and Dova shall have primary responsibility to seek and/or obtain any necessary approvals of any Product Labeling and the Promotional Materials used in connection with the Product, and for determining whether the same requires approval.",
                "explanation": "Original text states 'sole responsibility' which is exclusive, meaning that Dova is entirely responsible for seeking and obtaining approvals. The changed text uses 'primary responsibility' which implies that Dova has the main responsibility but could share it with another party.",
                "location": "Section 5.1"
            },
            {
                "type": "Misaligned Terminology - In Text Contradiction",
                "original_text": "8.1.1 Valeant Property. Dova acknowledges that Valeant owns or is licensed to use certain Know-How relating to the proprietary sales and marketing information, methods and plans that has been independently developed or licensed by Valeant (such Know-How, the “Valeant Property”). The Parties agree that any improvement, enhancement or modification made, discovered, conceived, or reduced to practice by Valeant to any Valeant Property in performing its activities pursuant to this Agreement which is not primarily related to the Product, or which is not otherwise derived from the Confidential Information of Dova, shall be deemed Valeant Property. [***], Valeant hereby grants to Dova a fully paid-up, royalty free, non-transferable, non-exclusive license (with a limited right to sub-license to its Affiliates) to any Valeant Property that appears on, embodied on or contained in the Product materials or Product Labeling solely for use in connection with Dova’s promotion or other commercialization of the Product in the Territory.",
                "changed_text": "8.1.1 Valeant Assets. Dova acknowledges that Valeant owns or is licensed to use certain Know-How relating to the proprietary sales and marketing information, methods and plans that has been independently developed or licensed by Valeant (such Know-How, the “Valeant Assets”). The Parties agree that any improvement, enhancement or modification made, discovered, conceived, or reduced to practice by Valeant to any Valeant Assets in performing its activities pursuant to this Agreement which is not primarily related to the Product, or which is not otherwise derived from the Confidential Information of Dova, shall be deemed Valeant Assets. [***], Valeant hereby grants to Dova a fully paid-up, royalty free, non-transferable, non-exclusive license (with a limited right to sub-license to its Affiliates) to any Valeant Assets that appears on, embodied on or contained in the Product materials or Product Labeling solely for use in connection with Dova’s promotion or other commercialization of the Product in the Territory.",
                "explanation": "The original text uses 'Valeant Property' to describe the Know-How. By changing it to 'Valeant Assets', it creates ambiguity because the contract does not define the scope of 'assets'. It raises the question whether 'assets' also includes physical property, which could expand the scope of what Valeant licenses to Dova.",
                "location": "Section 8.1.1"
            }
        ]
    }
]